Previous 10 | Next 10 |
ABVC BioPharma (NASDAQ:ABVC) on Wednesday said it had entered into an agreement with Taiwan-based medical device company Orion BioTech to identify global licensing partners. As per the deal, ABVC will use its business relationships globally to find licensing partners for Orion products. In re...
Fremont, CA - ( NewMediaWire ) - May 25, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that it has been engaged by Orion BioTech, Inc., a medical device c...
Fremont, CA, May 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Maurizio Fava and Dr. Thomas La...
ABVC BioPharma press release (NASDAQ:ABVC): Q1 net loss of $6.08M Revenue of $25.66M (-90.2% Y/Y). For further details see: ABVC BioPharma reports Q1 results
FREMONT, CA, May 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results ...
WallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering PR Newswire JERSEY CITY, N.J. , May 16, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and instit...
Fremont, CA - ( NewMediaWire ) - May 13, 2022 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has engaged the FreeMind Group to help ABVC explore and identify...
WallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering PR Newswire JERSEY CITY, N.J. , May 12, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and instituti...
ABVC BioPharma (NASDAQ:ABVC) on Thursday announced a $4.2M registered direct offering. ABVC will issue and sell 2M shares and warrants to purchase up to 2M shares to certain institutional investors, at a purchase price of $2.11/share and accompanying warrant. The warrants will be immediately ...
Fremont, CA - ( NewMediaWire ) - May 12, 2022 - ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC) today announced that it has entered into securities purchase agreements with certain institutional investors for the issuance and sale of 2,000,000 sh...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will i...
FREMONT, CA - ( NewMediaWire ) - July 9, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II c...
FREMONT, CA - ( NewMediaWire ) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and it...